AR067195A1 - Metodos, conjuntos de elementos y compuestos para determinar la capacidad de respuesta al tratamiento con epotilonas de un trastorno patologico - Google Patents

Metodos, conjuntos de elementos y compuestos para determinar la capacidad de respuesta al tratamiento con epotilonas de un trastorno patologico

Info

Publication number
AR067195A1
AR067195A1 ARP080102775A ARP080102775A AR067195A1 AR 067195 A1 AR067195 A1 AR 067195A1 AR P080102775 A ARP080102775 A AR P080102775A AR P080102775 A ARP080102775 A AR P080102775A AR 067195 A1 AR067195 A1 AR 067195A1
Authority
AR
Argentina
Prior art keywords
treatment
pathological disorder
timp2
subject
epotilones
Prior art date
Application number
ARP080102775A
Other languages
English (en)
Inventor
Jens Hoffmann
Stefanie Hammer
Anette Sommer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR067195A1 publication Critical patent/AR067195A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)

Abstract

Reivindicacion 1: Un método para determinar la capacidad de respuesta potencial de un sujeto al tratamiento de un trastorno patologico con una epotilona, caracterizado porque dicho método comprende analizar en una muestra de dicho sujeto el nivel de expresion de al menos un gen, o la proteína codificada por el mismo, en donde la proteína se selecciona del grupo formado por una isoforma del citocromo P (CYP), una epoxido hidrolasa microsomica (EPHX1), epoxido hidrolasa citoplasmática (EPHX2) , carboxilesterasa 2 (CES2) , p53 (TP53) miembro de interaccion Fas pro-apoptotica (DAXX), neuregulina 1 (NRG1), factor de crecimiento de hepatocitos (HGF), distrofina (DMD), UGT1A1, UGT1A3, UGT1A4, UGT1A8, UGT1A10, VEGF (VEGFA), GLUT1 (SLC2A1), ALDOC, heme oxigenasa (HMOX1), NIP3 (BNIP3), BNIP3L, carboanhidrasas, 2, 9 y 12 (CA2, CA9, CA12), PGK1, transferrina (TF), HIF-prolilhidroxilasa (EGLN3), E2F3, EIF4E y EIF4ABP1, EFA4, ITGA6, KIFAP3, TIMP2, RPS6KB1, TIMP2, FSHPRH1 o cualquier combinacion de los mismos.
ARP080102775A 2007-06-29 2008-06-27 Metodos, conjuntos de elementos y compuestos para determinar la capacidad de respuesta al tratamiento con epotilonas de un trastorno patologico AR067195A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07111484A EP2009114A1 (en) 2007-06-29 2007-06-29 Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones

Publications (1)

Publication Number Publication Date
AR067195A1 true AR067195A1 (es) 2009-09-30

Family

ID=38610790

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102775A AR067195A1 (es) 2007-06-29 2008-06-27 Metodos, conjuntos de elementos y compuestos para determinar la capacidad de respuesta al tratamiento con epotilonas de un trastorno patologico

Country Status (7)

Country Link
US (1) US20090076098A1 (es)
EP (2) EP2009114A1 (es)
JP (1) JP2010531985A (es)
AR (1) AR067195A1 (es)
CA (1) CA2690481A1 (es)
TW (1) TW200907341A (es)
WO (1) WO2009003706A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2536748B1 (en) * 2010-02-18 2014-08-20 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
CA2847525A1 (en) * 2011-09-12 2013-03-21 Universiteit Gent Neuregulin-1-based prognosis and therapeutic stratification of colorectal cancer
KR101583546B1 (ko) * 2014-04-09 2016-01-11 국립암센터 유전자 다형성을 이용한 소라페닙 치료에 대한 반응성 예측방법
BR112018007673A2 (pt) * 2015-10-16 2018-11-06 Univ Rice William M ?análogos de epotilona, métodos de síntese, métodos de tratamento e conjugados de fármaco dos mesmos?
CN109387630A (zh) * 2017-08-14 2019-02-26 杭州源昶医药科技有限公司 用于预测吉西他滨药物敏感性的生物标记物及其用途
US12018327B2 (en) 2018-03-01 2024-06-25 The Regents Of The University Of California Methods and compositions relating to epoxide hydrolase genes
CN110257352B (zh) * 2019-06-30 2021-04-27 陕西斯戴木生物科技有限公司 一种环氧化物水解酶及其用途
CN115290774B (zh) * 2022-07-21 2023-07-21 重庆医科大学 尿苷二磷酸葡萄糖醛酸在制备用于检测肝癌试剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6623960B1 (en) * 1999-02-12 2003-09-23 The United States Of America As Represented By The Department Of Health And Human Services Agents that bind to and inhibit human cytochrome P450 2C8, 2C9, 2C18 and 2C19
JP2005532036A (ja) * 2002-01-09 2005-10-27 理化学研究所 癌プロフィール
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
WO2006010585A1 (en) * 2004-07-26 2006-02-02 Novartis Ag Epothilone combinations
WO2006037993A2 (en) * 2004-10-02 2006-04-13 Auvation Limited Cancer markers
AU2005299767A1 (en) * 2004-10-21 2006-05-04 The Penn State Research Foundation Eph receptor tumor biomarkers
US20060121511A1 (en) * 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
US20110104664A1 (en) * 2006-03-31 2011-05-05 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to micortubule-stabilizing agents
CN101415420B (zh) * 2006-04-05 2012-09-05 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
WO2007140299A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals

Also Published As

Publication number Publication date
CA2690481A1 (en) 2009-01-08
EP2173903A2 (en) 2010-04-14
JP2010531985A (ja) 2010-09-30
WO2009003706A2 (en) 2009-01-08
EP2009114A1 (en) 2008-12-31
WO2009003706A3 (en) 2009-02-26
TW200907341A (en) 2009-02-16
US20090076098A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
AR067195A1 (es) Metodos, conjuntos de elementos y compuestos para determinar la capacidad de respuesta al tratamiento con epotilonas de un trastorno patologico
Karabicici et al. Doxorubicin‐induced senescence promotes stemness and tumorigenicity in EpCAM−/CD133− nonstem cell population in hepatocellular carcinoma cell line, HuH‐7
Habbig et al. The ciliopathy disease protein NPHP9 promotes nuclear delivery and activation of the oncogenic transcriptional regulator TAZ
Candeias et al. Cancer‐specific mutations in p53 induce the translation of Δ160p53 promoting tumorigenesis
Xian et al. HMGA1 amplifies Wnt signalling and expands the intestinal stem cell compartment and Paneth cell niche
Shriver et al. Loss of giant obscurins from breast epithelium promotes epithelial-to-mesenchymal transition, tumorigenicity and metastasis
Torii et al. Identification of PPM1D as an essential Ulk1 phosphatase for genotoxic stress‐induced autophagy
Zhang et al. NANOG modulates stemness in human colorectal cancer
Fareh et al. Cell-based therapy using miR-302-367 expressing cells represses glioblastoma growth
Lin et al. Nanoparticle delivery of miR-34a eradicates long-term-cultured breast cancer stem cells via targeting C22ORF28 directly
Wiel et al. Endoplasmic reticulum calcium release through ITPR2 channels leads to mitochondrial calcium accumulation and senescence
Zhu et al. MiR-302c inhibits tumor growth of hepatocellular carcinoma by suppressing the endothelial-mesenchymal transition of endothelial cells
Moughamian et al. Dynactin is required for transport initiation from the distal axon
Comisso et al. OCT4 controls mitotic stability and inactivates the RB tumor suppressor pathway to enhance ovarian cancer aggressiveness
Palmieri et al. HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents
Artibani et al. WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel
Wang et al. HIF-2α-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia
Shiota et al. P300/CBP‐associated factor regulates Y‐box binding protein‐1 expression and promotes cancer cell growth, cancer invasion and drug resistance
Fagoonee et al. The RNA binding protein ESRP1 fine-tunes the expression of pluripotency-related factors in mouse embryonic stem cells
Ali et al. Gain-of-function of mutant p53: mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells
Miyata et al. Platelet‐derived growth factor‐BB (PDGF‐BB) induces differentiation of bone marrow endothelial progenitor cell‐derived cell line TR‐BME2 into mural cells, and changes the phenotype
Lin et al. Knockdown of OCT4 suppresses the growth and invasion of pancreatic cancer cells through inhibition of the AKT pathway
Mondal et al. Δ133p53α, a natural p53 isoform, contributes to conditional reprogramming and long-term proliferation of primary epithelial cells
Salomé et al. A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling
Chen et al. CPSF4 activates telomerase reverse transcriptase and predicts poor prognosis in human lung adenocarcinomas

Legal Events

Date Code Title Description
FB Suspension of granting procedure